We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Monsanto, Dow Chemical Ink Deal on EXZACT Tech Platform
Read MoreHide Full Article
Monsanto Company and a wholly owned subsidiary of The Dow Chemical Company (DOW - Free Report) , Dow AgroSciences LLC, have signed a new agreement on the premium EXZACT technology platform. The companies have joined forces to research and commercially develop new varieties of crop solutions across the research portfolio of Monsanto.
This non-exclusive global option and licensing deal signed by Monsanto and Dow AgroSciences is likely to offer next-generation crop developments to farmers with the help of the EXZACT Precision Technology of the latter.
Dow AgroSciences has created EXZACT technology under a unique collaboration and licensing contract with Sangamo BioSciences, Inc. It is a type of genome-editing technology used to produce crop lines and varieties with enhanced traits.
The companies intend to deliver breakthrough technologies within the agricultural chemical’s market through the above-mentioned agreement. Financial terms of the deal remain undisclosed.
Moving Forward
Monsanto recently accepted Bayer AG’s (BAYRY - Free Report) all-cash $66-billion buyout offer. However, the deal has not gained any regulatory sanction yet.
Share price of this Zacks Rank #3 (Hold) stock was $102.47 as on Oct 3, 2016.
Over the last 60 days, the Zacks Consensus Estimate for the stock has been revised upward by 42.4% for fiscal 2016 and 5.9% for fiscal 2017.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Monsanto, Dow Chemical Ink Deal on EXZACT Tech Platform
Monsanto Company and a wholly owned subsidiary of The Dow Chemical Company (DOW - Free Report) , Dow AgroSciences LLC, have signed a new agreement on the premium EXZACT technology platform. The companies have joined forces to research and commercially develop new varieties of crop solutions across the research portfolio of Monsanto.
This non-exclusive global option and licensing deal signed by Monsanto and Dow AgroSciences is likely to offer next-generation crop developments to farmers with the help of the EXZACT Precision Technology of the latter.
Dow AgroSciences has created EXZACT technology under a unique collaboration and licensing contract with Sangamo BioSciences, Inc. It is a type of genome-editing technology used to produce crop lines and varieties with enhanced traits.
The companies intend to deliver breakthrough technologies within the agricultural chemical’s market through the above-mentioned agreement. Financial terms of the deal remain undisclosed.
Moving Forward
Monsanto recently accepted Bayer AG’s (BAYRY - Free Report) all-cash $66-billion buyout offer. However, the deal has not gained any regulatory sanction yet.
Share price of this Zacks Rank #3 (Hold) stock was $102.47 as on Oct 3, 2016.
MONSANTO CO-NEW Price
MONSANTO CO-NEW Price | MONSANTO CO-NEW Quote
The company is slated to report its fiscal fourth-quarter 2016 results on Oct 5 before the opening bell.
Stocks that Warrant a Look
Limoneira Company (LMNR - Free Report) currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Over the last 60 days, the Zacks Consensus Estimate for the stock has been revised upward by 42.4% for fiscal 2016 and 5.9% for fiscal 2017.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>